c1k
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 20, 2022 (NCT05980065)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Protein kinase C (PKC)INHIBITOR
Protein kinase C (PKC) inhibitor
- Serine/threonine-protein kinase D3 (PRKD3) ↗
- Protein kinase C iota type (PRKCI) ↗
- Protein kinase C alpha type (PRKCA) ↗
- Protein kinase C gamma type (PRKCG) ↗
- Protein kinase C delta type (PRKCD) ↗
- Protein kinase C beta type (PRKCB) ↗
- Protein kinase C zeta type (PRKCZ) ↗
- Protein kinase C epsilon type (PRKCE) ↗
- Protein kinase C eta type (PRKCH) ↗
- Serine/threonine-protein kinase D1 (PRKD1) ↗
- Protein kinase C theta type (PRKCQ) ↗
- Protein kinase C zeta
- Protein kinase C epsilon
- Protein kinase C gamma
- Protein kinase C nu
- Protein kinase C iota
- Protein kinase C mu
- Protein kinase C eta
- Protein kinase C alpha
- Protein kinase C beta
- Protein kinase C delta
- Protein kinase C theta
- Protein kinase C, PKC; classical/novel
- PKC alpha and beta-2
- Protein kinase C iota type/zeta type
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05701644 | Phase 1 | Jan 2, 2023 | Ensol Bioscience |
| NCT05980065 | Phase 1 | Dec 20, 2022 | Seoul National University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ensol Bioscience | For profit | 1 | 1 | 1 | 2023 |
| Seoul National University | Academic/Hospital | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1